{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:57:25Z","timestamp":1773838645871,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T00:00:00Z","timestamp":1704499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40273-023-01346-8","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T19:02:05Z","timestamp":1704567725000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia"],"prefix":"10.1007","volume":"42","author":[{"given":"Dong-Won","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,6]]},"reference":[{"issue":"1","key":"1346_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1346_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1182\/hematology.2020000086","volume":"2020","author":"C Moreno","year":"2020","unstructured":"Moreno C. Standard treatment approaches for relapsed\/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy. Hematol Am Soc Hematol Educ Program. 2020;2020(1):33\u201340. https:\/\/doi.org\/10.1182\/hematology.2020000086.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"Suppl. 2","key":"1346_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/ajh.26683","volume":"97","author":"JA Woyach","year":"2022","unstructured":"Woyach JA. Management of relapsed\/refractory chronic lymphocytic leukemia. Am J Hematol. 2022;97(Suppl. 2):S11\u20138. https:\/\/doi.org\/10.1002\/ajh.26683.","journal-title":"Am J Hematol"},{"issue":"Spec Future","key":"1346_CR4","first-page":"66","volume":"8","author":"LA Raedler","year":"2015","unstructured":"Raedler LA. Imbruvica (ibrutinib), first-in-class Bruton\u2019s tyrosine kinase inhibitor, receives expanded indications for patients with relapsed chronic lymphocytic leukemia. Am Health Drug Benefits. 2015;8(Spec Future):66\u20139.","journal-title":"Am Health Drug Benefits."},{"issue":"12","key":"1346_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353\u201363. https:\/\/doi.org\/10.1002\/ajh.25638.","journal-title":"Am J Hematol"},{"issue":"5","key":"1346_CR6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874\u20139. https:\/\/doi.org\/10.3324\/haematol.2017.182907.","journal-title":"Haematologica"},{"issue":"17","key":"1346_CR7","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, Yu D, Zhou C, Shi G, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62(17):7923\u201340. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00687.","journal-title":"J Med Chem"},{"issue":"4","key":"1346_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2211582.","journal-title":"N Engl J Med"},{"issue":"6","key":"1346_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","volume":"20","author":"WG Wierda","year":"2022","unstructured":"Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN Guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022;20(6):622\u201334. https:\/\/doi.org\/10.6004\/jnccn.2022.0031.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"1346_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"issue":"2","key":"1346_CR11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","volume":"35","author":"Q Chen","year":"2017","unstructured":"Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, et al. Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States. J Clin Oncol. 2017;35(2):166\u201374. https:\/\/doi.org\/10.1200\/JCO.2016.68.2856.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1346_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","volume":"103","author":"AR Mato","year":"2018","unstructured":"Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511\u20137. https:\/\/doi.org\/10.3324\/haematol.2018.193615.","journal-title":"Haematologica"},{"issue":"12","key":"1346_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3324\/haematol.2016.144576","volume":"101","author":"M Winqvist","year":"2016","unstructured":"Winqvist M, Asklid A, Andersson PO, Karlsson K, Karlsson C, Lauri B, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program: a study from the Swedish Chronic Lymphocytic Leukemia Group. Haematologica. 2016;101(12):1573\u201380. https:\/\/doi.org\/10.3324\/haematol.2016.144576.","journal-title":"Haematologica"},{"issue":"12","key":"1346_CR14","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","volume":"21","author":"P Abrisqueta","year":"2021","unstructured":"Abrisqueta P, Loscertales J, Terol MJ, Ram\u00edrez Payer \u00c1, Ortiz M, P\u00e9rez I, et al. Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study). Clin Lymphoma Myeloma Leuk. 2021;21(12):e985\u201399. https:\/\/doi.org\/10.1016\/j.clml.2021.07.022.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"1346_CR15","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","volume":"101","author":"UK Cll Forum","year":"2016","unstructured":"UK Cll Forum. Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563\u201372. https:\/\/doi.org\/10.3324\/haematol.2016.147900.","journal-title":"Haematologica"},{"issue":"1","key":"1346_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/heapol\/czz127","volume":"35","author":"M Haacker","year":"2020","unstructured":"Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107\u201314. https:\/\/doi.org\/10.1093\/heapol\/czz127.","journal-title":"Health Policy Plan"},{"key":"1346_CR17","unstructured":"Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials: extrapolation with patient-level data. 2011. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf. Accessed 13 Aug 2023."},{"key":"1346_CR18","unstructured":"Mitchell M. Engauge digitizer software. http:\/\/markummitchell.github.io\/engauge-digitizer. Accessed 28 Dec 2023."},{"key":"1346_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. https:\/\/doi.org\/10.1186\/1471-2288-12-9.","journal-title":"BMC Med Res Methodol"},{"key":"1346_CR20","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. Accessed 28 Dec 2023."},{"key":"1346_CR21","unstructured":"Social Security. Actuarial life table. https:\/\/www.ssa.gov\/oact\/STATS\/table4c6.html. Accessed 23 Aug 2023."},{"key":"1346_CR22","unstructured":"Lexicomp. https:\/\/www.wolterskluwer.com\/en\/solutions\/lexicomp\/lexicomp. Accessed 23 Apr 2023."},{"issue":"10","key":"1346_CR23","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","volume":"25","author":"N Alrawashdh","year":"2022","unstructured":"Alrawashdh N, McBride A, Erstad B, Sweasy J, Persky DO, Abraham I. Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia. Value Health. 2022;25(10):1685\u201395. https:\/\/doi.org\/10.1016\/j.jval.2022.04.001.","journal-title":"Value Health."},{"issue":"9","key":"1346_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1634\/theoncologist.2018-0019","volume":"24","author":"C Reyes","year":"2019","unstructured":"Reyes C, Engel-Nitz NM, DaCosta BS, Ravelo A, Ogale S, Bancroft T, et al. Cost of disease progression in patients with chronic lymphocytic leukemia, acute myeloid leukemia, and non-Hodgkin\u2019s lymphoma. Oncologist. 2019;24(9):1219\u201328. https:\/\/doi.org\/10.1634\/theoncologist.2018-0019.","journal-title":"Oncologist"},{"issue":"5","key":"1346_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14737167.2023.2196408","volume":"23","author":"T Munir","year":"2023","unstructured":"Munir T, Genovez V, Genestier V, Ryan K, Liljas B, Gaitonde P. Cost-effectiveness of acalabrutinib regimens in treatment-na\u00efve chronic lymphocytic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 2023;23(5):579\u201389. https:\/\/doi.org\/10.1080\/14737167.2023.2196408.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1346_CR26","unstructured":"National Cancer Institute. Financial burden of cancer care. https:\/\/progressreport.cancer.gov\/after\/economic_burden. Accessed 25 Aug 2023."},{"key":"1346_CR27","unstructured":"Federal Reserve Economic Data. Consumer price index for all urban consumers: medical care in U.S. City average. https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL. Accessed 23 Aug 2023."},{"key":"1346_CR28","unstructured":"National Institute for Health and Care Excellence. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. 2019. http:\/\/www.nice.org.uk\/guidance\/ta561. Accessed 29 Nov 2023."},{"issue":"17","key":"1346_CR29","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood.2020004922","volume":"136","author":"KK Patel","year":"2020","unstructured":"Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136(17):1946\u201355. https:\/\/doi.org\/10.1182\/blood.2020004922.","journal-title":"Blood"},{"issue":"15","key":"1346_CR30","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","volume":"2","author":"JI Barnes","year":"2018","unstructured":"Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, et al. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2(15):1946\u201356. https:\/\/doi.org\/10.1182\/bloodadvances.2017015461.","journal-title":"Blood Adv"},{"issue":"15","key":"1346_CR31","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1001\/jama.2023.1792","volume":"329","author":"PJ Neumann","year":"2023","unstructured":"Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990\u20132021. JAMA. 2023;329(15):1312\u20134. https:\/\/doi.org\/10.1001\/jama.2023.1792.","journal-title":"JAMA"},{"issue":"12","key":"1346_CR32","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s40273-018-0697-3","volume":"36","author":"AJ Hatswell","year":"2018","unstructured":"Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics. 2018;36(12):1421\u20136. https:\/\/doi.org\/10.1007\/s40273-018-0697-3.","journal-title":"Pharmacoeconomics"},{"key":"1346_CR33","unstructured":"National Cancer Institute. Cancer Stat Facts: leukemia: chronic lymphocytic leukemia (CLL). https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed 28 Nov 2023."},{"issue":"5","key":"1346_CR34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s10198-021-01398-7","volume":"23","author":"M Barbier","year":"2022","unstructured":"Barbier M, Durno N, Bennison C, \u00d6rtli M, Knapp C, Schwenkglenks M. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed\/refractory chronic lymphocytic leukemia in Switzerland. Eur J Health Econ. 2022;23(5):837\u201346. https:\/\/doi.org\/10.1007\/s10198-021-01398-7.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1346_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro RI, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1346_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40258-019-00496-1","volume":"17","author":"RA Vreman","year":"2019","unstructured":"Vreman RA, Geenen JW, H\u00f6vels AM, Goettsch WG, Leufkens HGM, Al MJ. Phase I\/II clinical trial-based early economic evaluation of acalabrutinib for relapsed chronic lymphocytic leukaemia. Appl Health Econ Health Policy. 2019;17(6):883\u201393. https:\/\/doi.org\/10.1007\/s40258-019-00496-1.","journal-title":"Appl Health Econ Health Policy"},{"issue":"5","key":"1346_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/bjh.17994","volume":"196","author":"G Cull","year":"2022","unstructured":"Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, et al. Zanubrutinib for treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I\/II AU-003 study. Br J Haematol. 2022;196(5):1209\u201318. https:\/\/doi.org\/10.1111\/bjh.17994.","journal-title":"Br J Haematol"},{"issue":"3","key":"1346_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1400376.","journal-title":"N Engl J Med"},{"issue":"26","key":"1346_CR39","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","volume":"379","author":"JA Woyach","year":"2018","unstructured":"Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1812836.","journal-title":"N Engl J Med"},{"issue":"4","key":"1346_CR40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jval.2020.10.016","volume":"24","author":"TA Tai","year":"2021","unstructured":"Tai TA, Latimer NR, Benedict \u00c1, Kiss Z, Nikolaou A. Prevalence of immature survival data for anti-cancer drugs presented to the National Institute for Health and Care Excellence and impact on decision making. Value Health. 2021;24(4):505\u201312. https:\/\/doi.org\/10.1016\/j.jval.2020.10.016.","journal-title":"Value Health."},{"key":"1346_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_10002842","volume":"41","author":"NB Leighl","year":"2021","unstructured":"Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41:1\u201312. https:\/\/doi.org\/10.1200\/EDBK_10002842.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"1346_CR42","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","volume":"19","author":"B Woods","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929\u201335. https:\/\/doi.org\/10.1016\/j.jval.2016.02.017.","journal-title":"Value Health."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01346-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01346-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T20:27:39Z","timestamp":1710361659000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01346-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,6]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1346"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01346-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,6]]},"assertion":[{"value":"11 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dong-Won Kang, Li Wang, Nicholas J. Short, Alessandra Ferrajoli, Yucai Wang, Shouhao Zhou, and Chan Shen have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The ALPINE trial data were obtained from the original article: Brown et al. []. Other input data were obtained from original articles and publicly available data. The data are available upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"CS and SZ developed the concept and design of the study. D-WK developed the model and collected and analyzed the data. All authors interpreted the data. D-WK and CS wrote the first draft. All authors contributed to the critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript. CS and SZ supervised the study.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}